Long-acting RSV monoclonal antibodies in infant prophylaxis — the single-injection passive immunization (nirsevimab/Beyfortus) providing five-month protection against RSV lower respiratory tract disease in all infants regardless of gestational age or health status representing the most significant preventive advance in pediatric infectious disease — create the most universally applicable market opportunity, with the Respiratory Syncytial Virus (RSV) Therapeutics Market reflecting long-acting mAbs as the infant protection commercial driver.

RSV disease burden — the approximately sixty-four million annual RSV infections globally with three point six million hospitalizations and one hundred thousand deaths in children under five years, with infants under six months at highest risk creating the urgent prevention imperative. RSV the leading cause of infant hospitalization in developed countries, with approximately fifty-eight thousand to eighty thousand annual hospitalizations in US infants and estimated direct medical costs of one point five to two billion dollars.

Nirsevimab (Beyfortus) paradigm shift — the Sanofi/AstraZeneca extended half-life monoclonal antibody (YCYTE technology) providing approximately five months of protection with a single intramuscular dose at birth or before the RSV season creating the universal infant immunization model. Nirsevimab demonstrating approximately seventy-five to eighty percent efficacy against RSV LRTD requiring medical attention in the MELODY and MEDLEY trials, with FDA approval in 2023 and CDC recommendation for universal infant administration replacing the palivizumab (Synagis) risk-based approach.

Palivizumab to nirsevimab transition — the transition from the monthly Synagis injections (five doses per season, limited to high-risk preterm infants) to the single-dose Beyfortus for all infants creating the market displacement and volume expansion. Nirsevimab capturing approximately sixty to seventy percent of the RSV prophylaxis market within two years of launch, with palivizumab maintaining use in specific immunocompromised populations and regions with limited nirsevimab access.

Do you think maternal RSV vaccination (Abrysvo, Arexvy during pregnancy) will eventually replace infant monoclonal antibody prophylaxis, or will the variable transplacental antibody transfer, waning immunity by five to six months, and the need for timely pregnancy vaccination maintain nirsevimab as the standard infant protection strategy?

What are the approved RSV therapeutics and prophylactics? Infant prophylaxis: Nirsevimab (Beyfortus — Sanofi/AstraZeneca): Extended half-life mAb; single IM dose; 50mg (<5kg), 100mg (≥5kg); 5-month protection; universal infant indication; FDA approved 2023; Palivizumab (Synagis — Sobi): Monthly IM; 15mg/kg; 5 doses/season; high-risk preterm only; since 1998; Maternal vaccines: Abrysvo (Pfizer): RSVpreF; 24-36 weeks gestation; FDA approved 2023; Arexvy (GSK): RSVPreF3; 24-36 weeks gestation; FDA approved 2023; Adult vaccines: Abrysvo (Pfizer): 60+ years; Arexvy (GSK): 60+ years; mRESVIA (Moderna): 60+ years; Antivirals: Ribavirin (aerosol — limited, toxic); No approved small molecule antivirals; Cost: Nirsevimab — $495-990 per dose; Palivizumab — $1,000-1,500/month; Maternal vaccine — $200-300/dose; Adult vaccine — $200-300/dose.

How does nirsevimab compare to palivizumab and maternal vaccination in infant RSV protection? Efficacy: Nirsevimab — 75-80% vs. LRTD (medical attention); 90%+ vs. severe LRTD (hospitalization); Palivizumab — 45-55% vs. hospitalization (high-risk only); Maternal vaccine — 50-60% infant protection first 3-6 months; Duration: Nirsevimab — 5 months (single dose); Palivizumab — 1 month (requires 5 doses); Maternal — 3-6 months (waning); Population: Nirsevimab — all infants; Palivizumab — high-risk preterm (<29 weeks, chronic lung disease, congenital heart disease); Maternal — infants of vaccinated mothers; Access: Nirsevimab — supply constraints (2023-2024); demand exceeded production; expanding; Palivizumab — established supply; Maternal — pregnancy care access dependent; Cost-effectiveness: Nirsevimab — cost-saving at $300/dose; highly cost-effective at current pricing; Palivizumab — $6,000-8,000/season; limited to high-risk; Market: RSV therapeutics — $8-10B (2025); nirsevimab — $3-4B; maternal vaccines — $1-2B; adult vaccines — $3-4B; 20-25% CAGR.

#RSVTherapeutics #Nirsevimab #Beyfortus #InfantProphylaxis #RespiratorySyncytialVirus #PediatricInfectiousDisease